免疫学领域的共同研究及授权契约:2016年～2025年

本报告提供了前所未有的途径，可以全面了解世界领先的生物製药公司签署的免疫学相关合作和许可协议。

本报告提供了 2016 年至 2025 年 909 项免疫学相关交易的详细资讯。提供双方宣布的交易付款条款。这些数据为付款条款和其他贸易条款提供了有用的见解。

了解潜在合作伙伴谈判交易条款的弹性，可以为谈判过程提供重要的见解，让您了解在谈判条款时可以期望实现的目标。许多小型企业都希望有详细的付款条款，但当涉及如何付款以及如何转让权利时，细节决定成败。

本报告提供了当前协议交易和合作资料库中记录的自 2016 年以来宣布的合作和许可协议的综合列表，以及可用的财务条款，以及公司及其合作伙伴向美国证券交易委员会提交的实际许可协议文件的在线副本链接。

报告的第一部分提供有关免疫学交易和商业活动的资讯。第1章对报告进行了介绍，第2章分析了免疫学领域的交易趋势。

第 3 章介绍了免疫学领域已完成交易的财务条款和发展阶段。交易按标题价值、预付款、里程碑付款和特许费率列出并分为几个部分。

第 4 章回顾了在免疫学交易中最活跃的 25 家生物製药公司。对于与美国证券交易委员会 (SEC) 公开宣布的协议交易，可以透过目前协议交易和联盟资料库中的连结在线存取。

第 5 章全面深入地回顾了 2016 年以来达成或宣布的免疫学交易，并提供合约文件。每个交易标题都透过网路连结连结到实际合约文件的线上版本，从而可以轻鬆根据需要存取每个合约文件。

第 6 章提供了按目标列出的免疫学病例综合目录。

该报告还包含大量图表和图形，重点介绍了自 2016 年以来的免疫学病例趋势和活动。

此外，我们的综合贸易目录按公司 A-Z 和技术类型进行组织。每个交易标题都提供了一个指向在线交易记录的网络链接，并在可用的情况下提供合同文件，从而允许根据需要轻鬆访问每个文件。

主要优点

免疫学合作与授权协议为读者提供以下主要优势：

• 了解 2016 年以来的合约趋势
• 查看免疫学合作与许可机会
• 基准分析 - 确定交易的市场价值
• 财务条款 – 预付款、里程碑付款、特许权使用费
• 按公司 A-Z、治疗和技术类型划分的贸易目录
• 大额交易金额
• 最活跃的交易者
• 确定每笔交易的资产和条款
• 查阅合约文件－洞察交易结构
• 尽职调查 - 评估拟议交易条款对合作伙伴公司的适用性。
• 节省数百小时的研究时间

研究范围

• 免疫学合作与授权交易旨在让全球领先的生物製药公司更深入地了解免疫学趋势和交易结构。

回报内容

• 生物製药产业免疫学相关交易的趋势
• 合作与授权协议架构概述
• 免疫学领域交易记录目录，涵盖製药和生物技术
• 重要的免疫学交易
• 最活跃的免疫学许可公司

目录

摘要整理

第1章 简介

第2章 免疫学的交易趋势

• 简介
• 多年的免疫学的联盟
• 各交易类型免疫学领域的联盟
• 各业界的免疫学领域的联盟
• 各开发阶段的免疫学的联合
• 各技术类型的免疫学领域的联盟
• 各治疗适应症的免疫学领域的联盟

第3章 免疫学领域的联盟的金融交易条件

• 简介
• 公开免疫学领域的联盟相关财务条件
• 免疫学领域的联盟的主要价值
• 免疫学领域的交易的预付款
• 免疫学领域的交易的里程金
• 免疫学的特许权率

第4章 主要免疫学领域的交易和交易厂商

• 简介
• 在免疫学合作方面最活跃的公司
• 免疫学领域最活跃的交易者名单
• 各价值排序的顶级免疫学交易

第5章 免疫学契约文件名录

• 简介
• 免疫学领域的合作协议，可提供合约

第6章 按治疗标的免疫学领域的交易

• 简介
• 按免疫治疗标的交易
• 交易名录
• 交易目录 - 免疫学交易（按公司划分），2016 年至 2025 年
• 交易清单 - 免疫学交易（按技术类型划分）（2016 年至 2025 年）
• 定义交易类型
• 关于 Biopharma Research Ltd
• 当前合作伙伴关係
• 当前合约
• Current Partnering 的最新报告标题

Immunology Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the immunology deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 909 immunology deals from 2016 to 2025.

The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.

The initial chapters of this report provide an orientation of immunology dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in immunology dealmaking.

Chapter 3 covers the financial deal terms for deals signed in the immunology field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.

Chapter 4 provides a review of the top 25 most active biopharma companies in immunology dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.

Chapter 5 provides a comprehensive and detailed review of immunology deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of immunology deals listed by theraeutic target.

The report also includes numerous table and figures that illustrate the trends and activities in immunology deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Immunology Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse immunology collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Immunology Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of immunology trends and structure of deals entered into by leading biopharma companies worldwide.

Immunology Collaboration and Licensing Deals includes:

• Trends in immunology dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of immunology deal records covering pharmaceutical and biotechnology
• The leading immunology deals by value
• Most active immunology licensing dealmakers

In Immunology Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Immunology Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in immunology dealmaking

• 2.1. Introduction
• 2.2. Immunology partnering over the years
• 2.3. Immunology partnering by deal type
• 2.4. Immunology partnering by industry sector
• 2.5. Immunology partnering by stage of development
• 2.6. Immunology partnering by technology type
• 2.7. Immunology partnering by therapeutic indication

Chapter 3 - Financial deal terms for immunology partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for immunology partnering
• 3.3. Immunology partnering headline values
• 3.4. Immunology deal upfront payments
• 3.5. Immunology deal milestone payments
• 3.6. Immunology royalty rates

Chapter 4 - Leading immunology deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in immunology partnering
• 4.3. List of most active dealmakers in immunology
• 4.4. Top immunology deals by value

Chapter 5 - Immunology contract document directory

• 5.1. Introduction
• 5.2. Immunology partnering deals where contract document available

Chapter 6 - Immunology dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by immunology therapeutic target
• Deal directory
• Deal directory - Immunology deals by company A-Z 2016 to 2025
• Deal directory - Immunology deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Immunology partnering since 2016
• Figure 2: Immunology partnering by deal type since 2016
• Figure 3: Immunology partnering by industry sector since 2016
• Figure 4: Immunology partnering by stage of development since 2016
• Figure 5: Immunology partnering by technology type since 2016
• Figure 6: Immunology partnering by indication since 2016
• Figure 7: Immunology deals with a headline value
• Figure 8: Immunology deals with upfront payment values
• Figure 9: Immunology deals with milestone payment
• Figure 10: Immunology deals with royalty rates
• Figure 11: Active immunology dealmaking activity since 2016
• Figure 12: Top immunology deals by value since 2016